HAMP and chronic kidney disease: As other agents, an oral hypoxia-inducible factor (HIF)-prolyl hydroxylases (PHD) inhibitor—vadadustat (AKB-6548, Akebia Therapeutics Inc, Cambridge, MA, USA)—has been shown to increase Hb, mean absolute reticulocyte count and TIBC and reduced hepcidin and ferritin by stabilizing HIF in iron-replete ND-CKD patients receiving a minimum dose of OIT with or without ESA [209,210].